Surveillance of Levofloxacin Resistance in Helicobacter Pylori Isolates in Bogotá-Colombia (2009-2014)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jul 26

PMID 27454429

Citations 15

Authors

Alba A Trespalacios-Rangel

William Otero

Azucena Arevalo-Galvis

Raul A Poutou-Pinales

Emiko Rimbara

David Y Graham

Affiliations

Soon will be listed here.

Abstract

Increased resistance of Helicobacter pylori to clarithromycin and metronidazole has resulted in recommendation to substitute fluoroquinolones for eradication therapy. The aims of the study were to determine the prevalence and changes in primary levofloxacin resistance related to H. pylori gyrA sequences. The study utilized H. pylori strains isolated from patients undergoing gastroscopy in Bogotá, Colombia from 2009 to 2014. Levofloxacin susceptibility was assessed by agar dilution. Mutations in gyrA sequences affecting the quinolone resistance-determining region (QRDR) were evaluated by direct sequencing. Overall, the mean prevalence of primary levofloxacin resistance was 18.2% (80 of 439 samples). Resistance increased from 11.8% (12/102) in 2009 to 27.3% (21/77) in 2014 (p = 0.001). gyrA mutations in levofloxacin resistant strains were present in QRDR positions 87 and 91. The most common mutation was N87I (43.8%, 35/80) followed by D91N (28.8%, 23/80) and N87K (11.3%, 9/80). Levofloxacin resistance increased markedly in Colombia during the six-year study period. Primary levofloxacin resistance was most often mediated by point mutations in gyrA, with N87I being the most common QRDR mutation related to levofloxacin resistance.

Citing Articles

Multiplex PCR-Mass Spectrometry Mini-Sequencing Technology Detected Antibiotic Resistance of to Six Antibiotics.

Zhao F, Zhao X, Zhang H, He L, Meng F, Zhang J Int J Mol Sci. 2025; 26(4).

PMID: 40004094 PMC: 11855914. DOI: 10.3390/ijms26041632.

Helicobacter pylori Infection in Colombia: Phylogeny, Resistome, and Virulome.

Munoz A, Stepanian J, Solano-Gutierrez J, Vale F, Trespalacios-Rangel A APMIS. 2025; 133(2):e70003.

PMID: 39930978 PMC: 11811748. DOI: 10.1111/apm.70003.

Levofloxacin induces erythrocyte contraction leading to red cell death.

Aslam H, Sohail A, Shahid A, Khan M, Sharif M, Kausar R Drug Target Insights. 2024; 18:78-83.

PMID: 39386351 PMC: 11462248. DOI: 10.33393/dti.2024.3060.

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields.

Natsheh I, Alsaleh M, Alkhawaldeh A, Albadawi D, Darwish M, Shammout M Drug Target Insights. 2024; 18:8-19.

PMID: 38751378 PMC: 11094707. DOI: 10.33393/dti.2024.3019.

Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study.

Losurdo G, Mezzapesa M, Ditonno I, Piazzolla M, Pricci M, Girardi B Antibiotics (Basel). 2024; 13(4).

PMID: 38667013 PMC: 11047300. DOI: 10.3390/antibiotics13040336.

References

Blaser M . The versatility of Helicobacter pylori in the adaptation to the human stomach. J Physiol Pharmacol. 1997; 48(3):307-14. View

Arevalo-Galvis A, Trespalacios-Rangell A, Otero W, Mercado-Reyes M, Poutou-Pinales R . Prevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol J Microbiol. 2012; 61(1):33-40. View

Graham D, Lu H, Yamaoka Y . Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36. DOI: 10.2165/00003495-200868060-00001. View

Liou J, Chang C, Sheng W, Wang Y, Chen M, Lee Y . Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2010; 55(3):1123-9. PMC: 3067120. DOI: 10.1128/AAC.01131-10. View

Kocazeybek B, Bahar Tokman H . Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter. 2015; 21(4):251-60. DOI: 10.1111/hel.12272. View

Teh X, Khosravi Y, Lee W, Leow A, Loke M, Vadivelu J . Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. PLoS One. 2014; 9(7):e101481. PMC: 4086822. DOI: 10.1371/journal.pone.0101481. View

Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach L . Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol. 2005; 19(7):399-408. View

Liu Y, Ponsioen C, Xiao S, Tytgat G, Ten Kate F . Geographic pathology of Helicobacter pylori gastritis. Helicobacter. 2005; 10(2):107-13. DOI: 10.1111/j.1523-5378.2005.00304.x. View

Malfertheiner P, Megraud F, OMorain C, Atherton J, Axon A, Bazzoli F . Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5):646-64. DOI: 10.1136/gutjnl-2012-302084. View

10.

Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl A . Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2012; 62(1):34-42. DOI: 10.1136/gutjnl-2012-302254. View

11.

Fock K, Katelaris P, Sugano K, Ang T, Hunt R, Talley N . Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24(10):1587-600. DOI: 10.1111/j.1440-1746.2009.05982.x. View

12.

Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T . "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007; 39(8):782-9. DOI: 10.1016/j.dld.2007.05.016. View

13.

Megraud F . The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012; 5(2):103-9. PMC: 3296089. DOI: 10.1177/1756283X11432492. View

14.

Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L . Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 2009; 47(11):3600-7. PMC: 2772597. DOI: 10.1128/JCM.00744-09. View

15.

Podzorski R, Podzorski D, Wuerth A, Tolia V . Analysis of the vacA, cagA, cagE, iceA, and babA2 genes in Helicobacter pylori from sixty-one pediatric patients from the Midwestern United States. Diagn Microbiol Infect Dis. 2003; 46(2):83-8. DOI: 10.1016/s0732-8893(03)00034-8. View

16.

Testerman T, Morris J . Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014; 20(36):12781-808. PMC: 4177463. DOI: 10.3748/wjg.v20.i36.12781. View

17.

Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M . Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006; 11(4):243-9. DOI: 10.1111/j.1523-5378.2006.00415.x. View

18.

Alvarez A, Moncayo J, Santacruz J, Corredor L, Reinosa E, Martinez J . [Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia]. Rev Med Chil. 2009; 137(10):1309-14. DOI: /S0034-98872009001000005. View

19.

Bogaerts P, Berhin C, Nizet H, Glupczynski Y . Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006; 11(5):441-5. DOI: 10.1111/j.1523-5378.2006.00436.x. View

20.

Wang L, Cheng H, Hu F, Li J . Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol. 2010; 16(18):2272-7. PMC: 2868221. DOI: 10.3748/wjg.v16.i18.2272. View